indazoles has been researched along with Salivary Gland Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harada, H; Iwai, H; Kanda, A; Kawahara, A; Ohe, C; Sawada, S; Sengupta, B; Suzuki, K; Takeda, M; Uemura, Y | 1 |
| Florou, V; Garrido-Laguna, I; Gilcrease, GW; Maeda, P; Nevala-Plagemann, C; Whisenant, J | 1 |
| Bendell, J; Burris, HA; Dowlati, A; Infante, JR; Jones, SF; Kane, MP; Levinson, KT; Stein, MN; Suttle, AB; Tan, AR | 1 |
| Arcila, M; Bauer, T; Berger, M; Cam, NR; Christiansen, J; Dogan, S; Drilon, A; Farago, A; Ghossein, R; Gounder, M; Hechtman, J; Ho, AL; Hornby, Z; Hyman, DM; Katabi, N; Ladanyi, M; Li, G; Lim, J; Liu, SV; Luo, D; Maneval, EC; Multani, P; Ou, SH; Patel, M; Shaw, A; Shen, R; Shoemaker, RF; Wang, L; Wei, G | 1 |
1 trial(s) available for indazoles and Salivary Gland Neoplasms
| Article | Year |
|---|---|
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indazoles; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Sulfonamides; Treatment Outcome | 2014 |
3 other study(ies) available for indazoles and Salivary Gland Neoplasms
| Article | Year |
|---|---|
Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report.
Topics: Benzamides; Biomarkers, Tumor; Carcinoma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Indazoles; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Salivary Gland Neoplasms; Treatment Outcome | 2022 |
Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib.
Topics: Aza Compounds; Benzamides; Drug Resistance, Neoplasm; Humans; Indazoles; Mammary Analogue Secretory Carcinoma; Oncogene Proteins, Fusion; Parotid Gland; Protein Kinase Inhibitors; Salivary Gland Neoplasms | 2021 |
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
Topics: Adult; Benzamides; Biomarkers, Tumor; Carcinoma, Acinar Cell; Clinical Trials as Topic; Crizotinib; Diagnosis, Differential; Drug Resistance, Neoplasm; Female; Humans; In Situ Hybridization, Fluorescence; Indazoles; Mammary Analogue Secretory Carcinoma; Mutation; Oncogene Proteins, Fusion; Pyrazoles; Pyridines; Salivary Gland Neoplasms | 2016 |